Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer - Université de Rennes Access content directly
Journal Articles International Journal of Cancer Year : 2020

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

Benoît Rousseau
Dewi Vernerey
  • Function : Correspondent author
  • PersonId : 773789
  • IdRef : 199443882

Abstract

Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP-based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months, P = .65). Stratification on Eastern Cooperative Oncology Group (ECOG) PS showed similar results in PS 0-1 and 2. Median OS was not different between FP monotherapy, platinum- and irinotecan-based doublets (5.6 vs 7.1 vs 6.7 months, P = .68). Similar findings were observed in the Italian cohort (n = 174) and in the sensitivity analysis in pooled cohorts (n = 525). No L2 regimen seemed superior over others in the platinum resistant/refractory or sensitive subgroups. Our results suggest that FP monotherapy is as active as FP doublets in aBTC in L2, regardless of the patient PS and country, and could be a therapeutic option in this setting.
Fichier principal
Vignette du fichier
Neuzillet et al-2020-Fluropyrimidine single agent or doublet chemotherapy as second line treatment.pdf (5.5 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02929354 , version 1 (10-09-2020)

Identifiers

Cite

Cindy Neuzillet, Andrea Casadei‐gardini, Bertrand Brieau, Caterina Vivaldi, Giovanni Brandi, et al.. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147 (11), pp.3177-3188. ⟨10.1002/ijc.33146⟩. ⟨hal-02929354⟩
110 View
283 Download

Altmetric

Share

Gmail Facebook X LinkedIn More